A phase1 study of autologous engineered CD4+ and CD8+ T cells, HLA-A*11:01-restricted, KRAS G12V-specific, transgenic TCR; CD8α/β coreceptor and a FAS41BB switch receptor in patients with solid tumors
Publication Title
SITC Annual Meeting; November 6-10; Houston, TX. 2024;12(Suppl 2): 662
Document Type
Abstract
Publication Date
11-1-2024
Keywords
oregon; chiles
Area of Special Interest
Cancer
Specialty/Research Institute
Oncology
Comments
Mitchell S, Khan B, Payumo F, Gabriela Chiorean E, Gahvari Z, Randolph Hecht J, Hurwitz M, Leidner RS, Lenz H-J, Pelster M, Schoenfeld AJ, Punekar SR, Zhao D, Basu S, Nagorsen D